Terry McGuire brings over 35 years of successful early stage investing experience in medical and information technology companies to the Polaris Innovation Fund team.
Prior to starting Polaris in 1996, McGuire was a partner at Burr, Egan, Deleage & Co. investing in early stage medical and information technology companies. McGuire began his career in venture capital at Golder, Thoma and Cressey in Chicago.
As a venture capitalist, McGuire has invested in more than 80 companies. He also co-founded three companies: Inspire Pharmaceuticals (public and sold to Merck), AIR (sold to Alkermes) and MicroCHIPS (sold to Dare). Companies McGuire has supported have touched more than 60 million patients and directly saved over 400,000 lives. These companies have raised over $7 billion in equity and corporate capital. As a group, they have achieved a combined peak enterprise value of over $70 billion.
In 2015, McGuire was listed as one of Scientific American’s Worldview 100, visionaries who continue to reshape biotechnology and the world. In 2014, McGuire was chosen to receive the Irish America Healthcare & Life Sciences 50 Award. In 2013, McGuire was listed as one of Forbes’ Top Life Sciences Investors, and he received The Boston Irish Business Award. In 2011 and 2014, McGuire was listed in Forbes’ Midas 100 List of Top Tech Investors. He is also a recipient of the Massachusetts Society for Medical Research Award, and the Albert Einstein Award for Outstanding Achievement in the Life Sciences, awarded by Harvard and the City of Jerusalem. He was awarded an honorary doctorate degrees from Ohio Wesleyan University and Canisius College for his work in translational science.
In 2009, Terry helped create the Global Venture Capital Congress (GVCC), a gathering of venture capital leadership from around the world. For the past 13 years Terry has chaired the congress. The GVCC has worked to create cooperation among venture capital associations in areas as diverse as public policy, research and strategic topics including diversity and inclusion, taxation, and the global image of venture capital and private equity.
McGuire was formerly chairman of the National Venture Capital Association (NVCA). During his tenure as NVCA Chairman, McGuire testified before Congress for Dodd-Frank Wall Street Reform and Consumer Protection Act. In 2020, the NVCA presented Terry with The Outstanding Service Award, which recognizes the exceptional service of an NVCA director or member who has committed an extraordinary amount of time, resources, and dedication to association efforts that in turn benefits the entire venture community.
McGuire was formerly chairman of the board of the Thayer School of Engineering, Dartmouth College. He sits on the boards of The Arthur Rock Center for Entrepreneurship at Harvard Business School (HBS) and The Healthcare Initiative Advisory Board (HBS). McGuire also sits on The Brigham Research Institute’s Scientific Advisory Board. McGuire also serves on a number of public and private boards of directors, including Adimab, Alector, Invivyd, Jnana, Seer and Tectonic. He previously served on the boards of Cubist, Ironwood, Akamai, Acceleron, Kallyope and deCode, among others.
McGuire holds an MBA from Harvard Business School, an MS in engineering from The Thayer School at Dartmouth College, and a BS in physics and economics from Hobart College.
The endorsements of current or past portfolio company executives are provided as illustrative examples and designed to demonstrate the benefits to portfolio companies of partnering with us. These statements are primarily aimed at prospective portfolio companies and not intended to solicit investors. The portfolio companies covered in these endorsements do not represent all portfolio company investments we have made. The experiences highlighted in these testimonials are solely those of the executives profiled and may not necessarily represent or be indicative of the current, past, or future experiences of other portfolio companies. Past results and experiences discussed are not indicative, or a guarantee of future results and experiences. We have not provided cash or other type of compensation in exchange for receiving these endorsements. We do not believe there are typically any material conflicts associated with providing these endorsements. The compensation of our portfolio company executives is primarily driven by the performance of their respective portfolio companies and any discretion we exercise in such compensation determinations is not influenced by whether an executive has provided a favorable statement. Additionally, the economic interests of our portfolio companies’ executives are generally well-aligned with ours and those of our investors. Nevertheless, the fact that these endorsements have been provided by individuals whose compensation we exercise a certain level of control over may incentivize them to provide favorable evaluations of their experiences working with us.